資料包裝 - Pharmaprojects:醫藥品的R&D年度檢討:2017年

本報告提供產業最從可靠的醫藥品開發資料庫，Pharmaprojects，企業，每開發階段，及治療領域的研發產品線相關見解。

目錄

• 研發產品線規模:各年度
• 開發平台:各開發階段
• 臨床實驗階段趨勢
• 從階段II預註冊的開發平台藥物的認證等級的可能性分佈
• 醫藥品企業前25家公司:各開發平台規模
• 有活性開發平台的企業的總數
• R&D企業的分佈:據點地的各國各地區
• 研發產品線:治療各群組
• 治療分類前25名
• 疾病/適應症前25名
• 開發平台藥物前25名
• 生技藥品 vs. 非生技藥品在開發平台上佔的比例
• 開發平台:各給藥途徑
• 作用機制前25名 (藥理學)
• 藥物蛋白質標的前25名
• Pharmaprojects確認的新藥的蛋白質標的數:各年度
• 稀少藥或簡易檢討指定的藥物數的增加

Stay informed on industry R&D trends and perform your own in-depth analysis. This datapack presents the supporting data from our seminal white paper, Pharmaprojects Pharma R&D Annual Review 2017. Over the past 25 years, the pharma R&D sector has seen many twists and turns.

Included with your purchase, our white paper looks at developments in a year that saw some new players make the big time, while others hit skid row after one too many negative (clinical) reviews. Sourced from Pharmaprojects, the industry's most trusted clinical drug development database, the information included in this datapack covers multiple views of the R&D pipeline by company, development phase, therapy area, and more, allowing you to perform your own analysis and dive deeper into the underlying data.

Table of Contents

• Total R&D Pipeline Size by Year 2001-2017
• Pipeline by Development Phase
• Clinical Phase Trends 2007-2017
• Distribution of Likelihood of Approval Ratings for Pipeline Drugs in Phase II to Pre-registration
• Top 25 Pharma Companies by Size of Pipeline
• Total Number of Companies with Active Pipelines 2001-2017
• Distribution of R&D Companies by HQ Country/Region 2016 and 2017
• The R&D Pipeline by Therapy Group
• Top 25 Therapeutic Categories
• Top 25 Diseases/Indications
• Top 25 Origins of Pipeline Drugs
• Biological vs Non-biological Drugs as a Percentage of the Pipeline 1995-2017
• Pipeline by Delivery Route 2016 & 2017
• Top 25 Mechanisms of Action (Pharmacologies)
• Top 25 Drug Protein Targets
• Number of New Drug Protein Targets Identified by Pharmaprojects by Year
• Rise in Numbers of Drugs Receiving Orphan Drug Status or an Expedited Review Designation 2013-2016